How many clinical trials will have started in Prospera by Dec 31, 2026?
💡 What the odds say
Most likely: 3-5 at about a 48% chance — a coin toss.
The market is heavily concentrated on the 3-5 and 1-2 trial buckets, with 84% probability combined, reflecting concrete near-term trial announcements rather than speculative growth; the single biggest recent shift was the Natera-Eledon strategic partnership (Jun 25), which added a planned Phase 3 kidney transplant trial, making the 3-5 outcome the clear front-runner.
What's driving it
- • Natera and Eledon announced a strategic partnership for using Prospera monitoring in a planned Phase 3 kidney transplant trial (Business Wire, Jun 25), directly adding a high-profile trial to the count and pushing the 3-5 bucket above 50%.
- • Klothea Bio launched a Phase 1b clinical trial in Prospera (GlobeNewswire, Feb 19), contributing to the base of trials already started and supporting the 1-2 and 3-5 outcomes.
- • A lung transplant interventional study featuring Prospera was announced (News-Medical, Jan 27), indicating ongoing research interest in Prospera as a trial site, though its start date and count remain uncertain.
Why the front-runners lead
- • The Natera-Eledon Phase 3 trial is likely to start before the deadline given the partnership announcement and existing infrastructure, securing at least one trial in the 1-2 bucket and boosting the 3-5 outcome.
- • Klothea Bio's Phase 1b trial is already underway, providing a confirmed trial that anchors the lower bound of the count and supports the 1-2 and 3-5 outcomes.
- • Prospera's designation as a special economic zone with streamlined regulations (Business Insider, May 2) may attract additional trials from biotech firms, increasing the probability of multiple starts.
Why it's still open
- • If the Natera-Eledon trial or other announced trials fail to commence by the deadline due to regulatory or logistical delays, the count could fall to 0 or 1-2, as only Klothea's trial is confirmed started.
- • The 3-5 outcome dominates but faces competition from the 1-2 bucket (36%), which could overtake if only 1-2 trials materialize; a single setback for a planned trial could shift probability significantly.
- • The 6 or more outcome (4%) is a long shot, but if multiple new trial announcements emerge in the second half of 2026, the field could open up, though no such catalysts are yet visible in headlines.
What to watch
- • If Natera and Eledon announce a specific start date for their Phase 3 trial before end of 2026, odds for 3-5 will likely rise above 55% and 1-2 fall.
- • Any new clinical trial announcement in Prospera (e.g., from a major pharma or biotech) between now and December would increase the probability of 3-5 or even 6 or more, at the expense of 1-2 and 0.
- • Regulatory changes or negative news about Prospera's trial environment (e.g., safety concerns or legal challenges) could reduce the likelihood of any starts, benefiting the 0 and 1-2 outcomes.
AI-generated · grounded in recent news + odds · informational only, not advice. Verify on the source platform.
Data from Futuur’s public API, for informational purposes only. PredictPal is not affiliated with any platform and does not facilitate trading.
Discussion
Loading…
How it resolves
Resolved by Futuur per each question's rules. Futuur runs both play- and real-money sides — we show the real-money (crypto) price.
ⓘ A market settles under its own written rules, which can lag what looks decided in the news — so the price may not move to 100% the moment an outcome seems obvious.
View the official rules on Futuur ↗Related markets
Will over 100,000 people be conceived with the help of advanced embryo selection techniques by 2030?
The market sees advanced embryo selection as still niche and ethically fraught, but recent coverage of genetic optimization startups and IVF's expanding role in family planning suggests the technology is gaining momentum, making the 100,000-conception threshold plausible if regulatory and adoption barriers fall.
Yes ≈ 26% chance